Agilon Health
AGL
85.70
+2.30
+2.76%
Agilon Health
US · AGL
#3034 by market cap
Listed 2021
85.70
+2.30
+2.76%
Live - 5344 symbols - heartbeat 357s ago
· 2026-10-08 05:55
Pre-market
85.70
0.00%
After-hours
85.70
0.00%
- Market cap
- 1.44B
- P/E (TTM)i
- -6.03
- P/Bi
- 6.32
- EPSi
- -23.75
- Div yieldi
- 0.00%
- 52W posi
- 62%
Reader sentiment
Are you bullish or bearish on AGL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 97.37% +0.29pp
- Institutions
- 219 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund38.15%
Hedge Fund26.47%
VC/PE Fund24.45%
Public Company4.55%
Individual/Insider2.25%
Private Company2.11%
Family Office/Trust0.75%
Insurance Company0.62%
Government Pension Fund0.26%
Other0.39%
Top holders as of 2026-06-30
Clayton, Dubilier & Rice, LLC
23.82% · 4.00M sh
Morgan Stanley Investment Management Inc.
11.71% · 1.97M sh
North Peak Capital Management, LLC
8.84% · 1.49M sh
BlackRock
6.83% · 1.15M sh
AQR Capital Management
4.02% · 674.66K sh
Vanguard Capital Management, LLC
3.65% · 613.63K sh
The Goldman Sachs Group, Inc.
3.61% · 605.84K sh
Marshall Wace LLP
2.79% · 468.29K sh
Durable Capital Partners, LP
2.62% · 440.64K sh
D. E. Shaw & Co., L.P.
2.32% · 390.15K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Clayton, Dubilier & Rice, LLC | -- | 23.82% |
| Ronald Williams | Chairperson | 0.88% |
| Denise Zamore | Chief Legal Officer | 0.39% |
| Sharad Mansukani | Independent Director | 0.32% |
| Benjamin Shaker | Chief Markets Officer | 0.22% |
| Jeffrey Schwaneke | Independent Director | 0.11% |
| John Wulf | Director | 0.09% |
| Timothy Gertsch | Chief Accounting Officer | 0.08% |
| Karen McLoughlin | Independent Director | 0.04% |
| Silvana Battaglia | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-15 | Timothy Gertsch | Chief Accounting Officer | Sale to Issuer | -17 | $96.90 |
| 2026-07-31 | Denise Zamore | Chief Legal Officer | Sale to Issuer | -37 | $91.61 |
| 2026-06-30 | Jeffrey Schwaneke | Independent Director | Sale to Issuer | -2,311 | $111.74 |
| 2026-06-01 | Ronald Williams | Chairperson | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Sharad Mansukani | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Silvana Battaglia | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Diana McKenzie | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | Karen McLoughlin | Independent Director | Other Acquisition | +2,133 | -- |
| 2026-06-01 | John Wulf | Director | Other Acquisition | +2,133 | -- |
| 2026-05-31 | Denise Zamore | Chief Legal Officer | Sale to Issuer | -485 | $92.54 |
| 2026-05-23 | Timothy Gertsch | Chief Accounting Officer | Sale to Issuer | -8 | $86.39 |
| 2026-05-06 | Timothy O’Rourke | Chief Executive Officer | Other Acquisition | +120,000 | -- |
| 2026-05-06 | Timothy O’Rourke | Chief Executive Officer | Other Acquisition | +200,000 | -- |
| 2026-04-14 | Girish Venkatachaliah | Chief Technology Officer | Sale to Issuer | -426 | $22.68–26.88 |
| 2026-04-14 | Benjamin Shaker | Chief Markets Officer | Sale to Issuer | -675 | $22.68–26.88 |
| 2026-04-14 | Denise Zamore | Chief Legal Officer | Sale to Issuer | -240 | $22.68–26.88 |
| 2026-04-14 | Timothy Gertsch | Chief Accounting Officer | Sale to Issuer | -147 | $22.68–26.88 |
| 2026-03-31 | Jeffrey Schwaneke | Independent Director | Sale to Issuer | -1,662 | $9.75 |
| 2026-03-31 | Jeffrey Schwaneke | Independent Director | Other Acquisition | +75,000 | -- |
| 2026-03-31 | Girish Venkatachaliah | Chief Technology Officer | Sale to Issuer | -480 | $9.75 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 05:55:11 · For reference only, not investment advice and not tailored to your situation.